Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive…
Respiratory
-
-
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower…
-
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former…
-
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody…
-
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an…
-
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution…
-
Apnimed to seek approval for sleep apnoea pill after Phase III success
Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase III trial, with hopes to file…
-
EC approves BMS’ perioperative Opdivo and chemo for NSCLC
The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy…
-
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) inhaler for use with a…
-
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
